<p>Cartesian Therapeutics（纳斯达克股票代码：RNAC - 获取免费报告）在周五向投资者发布的一份报告中，投资分析师 Needham &amp; Company LLC 将其目标价格从 40.00 美元上调至 42.00 美元，Benzinga 报道。该券商目前对该股票给予 “买入” 评级。Needham &amp; Company LLC 的目标价格暗示该公司当前价格有 436.33% 的潜在上涨空间。</p>
<p>获取 <strong>Cartesian Therapeutics</strong> 的提醒：</p>
<p>其他几位分析师最近也对该股票发表了看法。BTIG Research 在 11 月 14 日的研究报告中将 Cartesian Therapeutics 的目标价格从 42.00 美元上调至 44.00 美元，并给予该公司 “买入” 评级。华尔街 Zen 在 11 月 8 日的研究报告中将 Cartesian Therapeutics 的评级从 “持有” 下调至 “卖出”。Weiss Ratings 在 12 月 29 日的报告中重申了对 Cartesian Therapeutics 的 “卖出（e+）” 评级。最后，HC Wainwright 在 11 月 19 日的报告中将 Cartesian Therapeutics 的目标价格从 40.00 美元下调至 30.00 美元，并对该股票给予 “买入” 评级。四位投资分析师对该股票给予 “买入” 评级，一位分析师对该公司给予 “卖出” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，平均目标价格为 38.50 美元。</p>
<p><strong>查看我们关于 RNAC 的最新报告</strong></p>
<h2>Cartesian Therapeutics 股票下跌 3.6%</h2>
<p>在周五的午盘交易中，纳斯达克：RNAC 的股票下跌 0.29 美元，报 7.83 美元。该公司交易了 42,503 股，而其平均交易量为 145,958 股。该公司的 50 日移动平均价格为 7.38 美元，200 日移动平均价格为 9.58 美元。该公司的市值为 2.0364 亿美元，市盈率为-5.07，贝塔值为 0.38。Cartesian Therapeutics 的 12 个月低点为 5.98 美元，12 个月高点为 20.12 美元。</p>
<p>Cartesian Therapeutics（纳斯达克股票代码：RNAC - 获取免费报告）最后一次公布季度财报是在 11 月 6 日。该公司报告本季度每股收益为（1.38 美元），低于市场共识预期的（0.81 美元）0.57 美元。该公司本季度的收入为 45 万美元，而分析师预期为 18 万美元。分析师预测 Cartesian Therapeutics 在当前年度的每股收益将为 4.56 美元。</p>
<h2>内部人士下注</h2>
<p>在其他新闻中，首席财务官 Blaine Davis 在 1 月 6 日的交易中出售了 10,591 股该公司的股票。股票以平均价格 6.82 美元出售，总价值为 72,230.62 美元。出售后，首席财务官直接持有该公司 121,220 股股票，估值约为 826,720.40 美元。这笔交易代表其持股比例下降了 8.03%。该交易已在证券交易委员会的备案中披露，相关信息可通过此链接访问。60.30% 的股票目前由公司内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>一些大型投资者最近调整了对 RNAC 的持股。Rhumbline Advisers 在第一季度将其在 Cartesian Therapeutics 的持股增加了 27.5%。Rhumbline Advisers 目前持有 13,006 股该公司的股票，价值 171,000 美元，此前在上个季度增持了 2,805 股。Miller Financial Services LLC 在第二季度购买了价值约 121,000 美元的 Cartesian Therapeutics 新股份。Virtus Investment Advisers LLC 在第二季度将其在 Cartesian Therapeutics 的持股增加了 12.5%。Virtus Investment Advisers LLC 目前持有 9,183 股该公司的股票，价值 95,000 美元，此前在此期间增持了 1,023 股。Marshall Wace LLP 在第二季度将其在 Cartesian Therapeutics 的持股增加了 114.0%。Marshall Wace LLP 目前持有 82,630 股该公司的股票，价值 859,000 美元，此前在此期间增持了 44,025 股。最后，683 Capital Management LLC 在第二季度将其在 Cartesian Therapeutics 的持股增加了 46.0%。683 Capital Management LLC 目前持有 219,000 股该公司的股票，价值 2,275,000 美元，此前在上个季度增持了 69,000 股。机构投资者和对冲基金持有该公司 86.95% 的股票。</p>
<h2>Cartesian Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Cartesian Therapeutics 在纳斯达克以 RNAC 为交易代码，是一家临床阶段的生物技术公司，专注于基于信使 RNA（mRNA）治疗的开发。该公司利用专有的 RNA 递送平台，诱导患者体内产生治疗性蛋白，旨在通过体内表达疾病修饰剂来解决一系列疾病。Cartesian 的技术旨在优化 mRNA 的稳定性、翻译效率和靶向递送，潜在应用涵盖肿瘤学、自身免疫疾病和罕见遗传病。</p>
<p>Cartesian 方法的核心是一个合成 mRNA 平台，结合了专有的脂质纳米颗粒（LNP）配方。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好五只股票而非 Cartesian Therapeutics</li>
<li>Elon 将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>请勿删除，立即阅读</li>
<li>该股票获得 94 分（满分 100 分）</li>
<li>股票代码揭晓：首次公开募股接入 “下一个 Elon Musk” 公司</li>
<li>自 2007 年以来首次：所有警告均已激活</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Uk5BQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Uk5BQw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Cartesian Therapeutics 吗？</h2>
<p>在考虑投资 Cartesian Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Cartesian Therapeutics 并不在名单上。</p>
<p>虽然 Cartesian Therapeutics 目前在分析师中获得了中性买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RNAC

<p>Needham & Company LLC 将 Cartesian Therapeutics (NASDAQ:RNAC) 的目标股价从 40.00 美元上调至 42.00 美元，维持 “买入” 评级。这表明从当前价格来看，潜在上涨幅度为 436.33%。其他分析师的看法不一，BTIG Research 将目标价上调至 44.00 美元，而 Wall Street Zen 则下调至 “卖出”。Cartesian 的股票目前交易价格为 7.83 美元，下跌 3.6%，市值为 2.0364 亿美元。该公司报告季度每股亏损 1.38 美元，未能达到预期，收入为 45 万美元</p>

<p>Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) had its price objective hoisted by investment analysts at Needham &amp; Company LLC from $40.00 to $42.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a &#34;buy&#34; rating on the stock. Needham &amp; Company LLC's price target would suggest a potential upside of 436.33% from the company's current price.</p>
<div class="lb-trans"><p>Cartesian Therapeutics（纳斯达克股票代码：RNAC - 获取免费报告）在周五向投资者发布的一份报告中，投资分析师 Needham &amp; Company LLC 将其目标价格从 40.00 美元上调至 42.00 美元，Benzinga 报道。该券商目前对该股票给予 “买入” 评级。Needham &amp; Company LLC 的目标价格暗示该公司当前价格有 436.33% 的潜在上涨空间。</p>
</div><p>Get <strong>Cartesian Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Cartesian Therapeutics</strong> 的提醒：</p>
</div><p>Several other analysts have also recently weighed in on the stock. BTIG Research raised their price objective on shares of Cartesian Therapeutics from $42.00 to $44.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, November 14th. Wall Street Zen cut shares of Cartesian Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, November 8th. Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of Cartesian Therapeutics in a report on Monday, December 29th. Finally, HC Wainwright cut their price target on shares of Cartesian Therapeutics from $40.00 to $30.00 and set a &#34;buy&#34; rating on the stock in a report on Wednesday, November 19th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $38.50.</p>
<div class="lb-trans"><p>其他几位分析师最近也对该股票发表了看法。BTIG Research 在 11 月 14 日的研究报告中将 Cartesian Therapeutics 的目标价格从 42.00 美元上调至 44.00 美元，并给予该公司 “买入” 评级。华尔街 Zen 在 11 月 8 日的研究报告中将 Cartesian Therapeutics 的评级从 “持有” 下调至 “卖出”。Weiss Ratings 在 12 月 29 日的报告中重申了对 Cartesian Therapeutics 的 “卖出（e+）” 评级。最后，HC Wainwright 在 11 月 19 日的报告中将 Cartesian Therapeutics 的目标价格从 40.00 美元下调至 30.00 美元，并对该股票给予 “买入” 评级。四位投资分析师对该股票给予 “买入” 评级，一位分析师对该公司给予 “卖出” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，平均目标价格为 38.50 美元。</p>
</div><p><strong>View Our Latest Report on RNAC</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 RNAC 的最新报告</strong></p>
</div><h2>Cartesian Therapeutics Stock Down 3.6%</h2>
<div class="lb-trans"><h2>Cartesian Therapeutics 股票下跌 3.6%</h2>
</div><p>Shares of NASDAQ:RNAC traded down $0.29 during midday trading on Friday, reaching $7.83. 42,503 shares of the company traded hands, compared to its average volume of 145,958. The firm's fifty day moving average price is $7.38 and its two-hundred day moving average price is $9.58. The firm has a market capitalization of $203.64 million, a price-to-earnings ratio of -5.07 and a beta of 0.38. Cartesian Therapeutics has a 12 month low of $5.98 and a 12 month high of $20.12.</p>
<div class="lb-trans"><p>在周五的午盘交易中，纳斯达克：RNAC 的股票下跌 0.29 美元，报 7.83 美元。该公司交易了 42,503 股，而其平均交易量为 145,958 股。该公司的 50 日移动平均价格为 7.38 美元，200 日移动平均价格为 9.58 美元。该公司的市值为 2.0364 亿美元，市盈率为-5.07，贝塔值为 0.38。Cartesian Therapeutics 的 12 个月低点为 5.98 美元，12 个月高点为 20.12 美元。</p>
</div><p>Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.57). The firm had revenue of $0.45 million during the quarter, compared to analysts' expectations of $0.18 million. Analysts forecast that Cartesian Therapeutics will post 4.56 earnings per share for the current year.</p>
<div class="lb-trans"><p>Cartesian Therapeutics（纳斯达克股票代码：RNAC - 获取免费报告）最后一次公布季度财报是在 11 月 6 日。该公司报告本季度每股收益为（1.38 美元），低于市场共识预期的（0.81 美元）0.57 美元。该公司本季度的收入为 45 万美元，而分析师预期为 18 万美元。分析师预测 Cartesian Therapeutics 在当前年度的每股收益将为 4.56 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, CFO Blaine Davis sold 10,591 shares of the firm's stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $6.82, for a total value of $72,230.62. Following the sale, the chief financial officer directly owned 121,220 shares in the company, valued at approximately $826,720.40. This trade represents a 8.03% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. 60.30% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，首席财务官 Blaine Davis 在 1 月 6 日的交易中出售了 10,591 股该公司的股票。股票以平均价格 6.82 美元出售，总价值为 72,230.62 美元。出售后，首席财务官直接持有该公司 121,220 股股票，估值约为 826,720.40 美元。这笔交易代表其持股比例下降了 8.03%。该交易已在证券交易委员会的备案中披露，相关信息可通过此链接访问。60.30% 的股票目前由公司内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of large investors have recently modified their holdings of RNAC. Rhumbline Advisers boosted its position in Cartesian Therapeutics by 27.5% during the first quarter. Rhumbline Advisers now owns 13,006 shares of the company's stock worth $171,000 after acquiring an additional 2,805 shares during the last quarter. Miller Financial Services LLC purchased a new stake in Cartesian Therapeutics in the second quarter valued at approximately $121,000. Virtus Investment Advisers LLC boosted its position in shares of Cartesian Therapeutics by 12.5% during the second quarter. Virtus Investment Advisers LLC now owns 9,183 shares of the company's stock worth $95,000 after buying an additional 1,023 shares during the period. Marshall Wace LLP increased its stake in Cartesian Therapeutics by 114.0% during the second quarter. Marshall Wace LLP now owns 82,630 shares of the company's stock worth $859,000 after purchasing an additional 44,025 shares during the period. Finally, 683 Capital Management LLC grew its stake in shares of Cartesian Therapeutics by 46.0% in the second quarter. 683 Capital Management LLC now owns 219,000 shares of the company's stock worth $2,275,000 after acquiring an additional 69,000 shares in the last quarter. Institutional investors and hedge funds own 86.95% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投资者最近调整了对 RNAC 的持股。Rhumbline Advisers 在第一季度将其在 Cartesian Therapeutics 的持股增加了 27.5%。Rhumbline Advisers 目前持有 13,006 股该公司的股票，价值 171,000 美元，此前在上个季度增持了 2,805 股。Miller Financial Services LLC 在第二季度购买了价值约 121,000 美元的 Cartesian Therapeutics 新股份。Virtus Investment Advisers LLC 在第二季度将其在 Cartesian Therapeutics 的持股增加了 12.5%。Virtus Investment Advisers LLC 目前持有 9,183 股该公司的股票，价值 95,000 美元，此前在此期间增持了 1,023 股。Marshall Wace LLP 在第二季度将其在 Cartesian Therapeutics 的持股增加了 114.0%。Marshall Wace LLP 目前持有 82,630 股该公司的股票，价值 859,000 美元，此前在此期间增持了 44,025 股。最后，683 Capital Management LLC 在第二季度将其在 Cartesian Therapeutics 的持股增加了 46.0%。683 Capital Management LLC 目前持有 219,000 股该公司的股票，价值 2,275,000 美元，此前在上个季度增持了 69,000 股。机构投资者和对冲基金持有该公司 86.95% 的股票。</p>
</div><h2>Cartesian Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Cartesian Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Cartesian Therapeutics, trading on NASDAQ under the symbol RNAC, is a clinical‐stage biotechnology company specializing in the development of messenger RNA (mRNA)-based therapeutics. The company leverages a proprietary RNA delivery platform to induce the production of therapeutic proteins within patients, aiming to address a range of diseases through in vivo expression of disease-modifying agents. Cartesian's technology is designed to optimize mRNA stability, translation efficiency and targeted delivery, with potential applications spanning oncology, autoimmune disorders and rare genetic conditions.</p>
<div class="lb-trans"><p>Cartesian Therapeutics 在纳斯达克以 RNAC 为交易代码，是一家临床阶段的生物技术公司，专注于基于信使 RNA（mRNA）治疗的开发。该公司利用专有的 RNA 递送平台，诱导患者体内产生治疗性蛋白，旨在通过体内表达疾病修饰剂来解决一系列疾病。Cartesian 的技术旨在优化 mRNA 的稳定性、翻译效率和靶向递送，潜在应用涵盖肿瘤学、自身免疫疾病和罕见遗传病。</p>
</div><p>At the core of Cartesian's approach is a synthetic mRNA platform that incorporates proprietary lipid nanoparticle (LNP) formulations.</p>
<div class="lb-trans"><p>Cartesian 方法的核心是一个合成 mRNA 平台，结合了专有的脂质纳米颗粒（LNP）配方。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Cartesian Therapeutics</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>Do not delete, read immediately</li>
<li>This stock gets a 94 out of 100</li>
<li>Ticker Revealed: Pre-IPO Access to &#34;Next Elon Musk&#34; Company</li>
<li>First Time Since 2007: All Warnings Active</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好五只股票而非 Cartesian Therapeutics</li>
<li>Elon 将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>请勿删除，立即阅读</li>
<li>该股票获得 94 分（满分 100 分）</li>
<li>股票代码揭晓：首次公开募股接入 “下一个 Elon Musk” 公司</li>
<li>自 2007 年以来首次：所有警告均已激活</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Uk5BQw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=RNAC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cartesian Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Cartesian Therapeutics 吗？</h2>
</div><p>Before you consider Cartesian Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Cartesian Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cartesian Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Cartesian Therapeutics 并不在名单上。</p>
</div><p>While Cartesian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cartesian Therapeutics 目前在分析师中获得了中性买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Cartesian Therapeutics（NASDAQ:RNAC）被 Needham & Company LLC 设定了新的目标价为 42.00 美元